AstraZeneca-Daiichi Sankyo Enhertu approved in EU for lung cancer Ruchika Sharma24 Oct 2023 1:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo’s (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the...
Merck-Daiichi Sankyo ink pact for patritumab deruxtecan,ifinatamab deruxtecan, raludotatug deruxtecan Ruchika Sharma22 Oct 2023 1:45 PM ISTDesigned using Daiichi Sankyo's proprietary DXd ADC technology to target and deliver a cytotoxic payload inside cancer cells that express a specific...
AstraZeneca Enhertu recommended for nod in EU by CHMP for HER2-mutant advanced non-small cell lung cancer Ruchika Sharma16 Sept 2023 1:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo’s (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for...
Daiichi Sankyo DS-3939 enters clinical development in patients across several types of advanced solid cancers Ruchika Sharma10 Sept 2023 3:54 PM ISTTokyo: Daiichi Sankyo has announced that the first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS-3939 in patients with...
Daiichi Sankyo submits sNDA for Omicron XBB.1.5-adapted COVID vaccine in Japan Ruchika Sharma10 Sept 2023 10:00 AM ISTTokyo: Daiichi Sankyo has announced that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and...
Daiichi Sankyo Enhertu approved in Japan as first HER2 directed therapy for patients with HER2 mutant metastatic lung cancer Ruchika Sharma25 Aug 2023 10:00 AM ISTTokyo: Daiichi Sankyo has announced that ENHERTU (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with...
Daiichi Sankyo to close Japanese RnD subsidiary Daiichi Sankyo RD Novare Ruchika Sharma8 Aug 2023 4:30 PM ISTTokyo: Daiichi Sankyo has announced that it has decided to close its Japanese research and development (R&D) subsidiary, Daiichi Sankyo RD Novare...
Daiichi Sankyo Daichirona for Intramuscular Injection approved for manufacturing, marketing as booster vaccination in Japan Ruchika Sharma2 Aug 2023 1:30 PM ISTDAICHIRONA for Intramuscular Injection is an mRNA vaccine against COVID-19 designed to produce antibodies against the receptor binding domain of the...
Daiichi Sankyo Vanflyta gets US FDA nod for patients with newly diagnosed FLT3-ITD positive AML Ruchika Sharma23 July 2023 12:00 PM ISTTokyo: Daiichi Sankyo has announced that VANFLYTA (quizartinib) has been approved by the U.S. Food and Drug Administration (FDA) in combination with...
Delhi HC permits Daiichi Sankyo to withdraw over Rs 20.5 crore deposited with court Ruchika Sharma26 April 2023 12:30 PM ISTNew Delhi: The Delhi High Court Monday permitted Japanese pharma major Daiichi Sankyo to withdraw over Rs 20.5 crore which was transmitted to the high...
USFDA extends review period for Daiichi Sankyo acute myeloid leukemia drug Quizartinib Ruchika Sharma23 April 2023 4:00 PM ISTQuizartinib is an oral, highly potent type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for...
AstraZeneca-Daiichi Sankyo Enhertu approved in China for breast cancer Ruchika Sharma25 Feb 2023 1:30 PM ISTUK: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in China as a monotherapy for the treatment of adult...
